Biovail/Depomed’s Glumetza Clears FDA For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies are highlighting potential dosing and tolerability advantages for Glumetza (metformin extended-release) to differentiate the drug in a crowded metformin market. Biovail is in discussions with several potential marketing partners for a U.S. launch of the antidiabetic.
You may also be interested in...
Depomed’s Glumetza Q3 Launch Will Be Executed By King
Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.
Depomed’s Glumetza Q3 Launch Will Be Executed By King
Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.
First Horizon To Promote Fortamet, Altroprev With 100-Rep Sales Force
Andrx divests extended-release metformin and extended-release lovastatin to First Horizon for upfront payment of $50 mil. First Horizon's promotional efforts will focus on growing Fortamet and stabilizing Altoprev's declining market share.